Page 163 - 南京医科大学学报自然科学版
P. 163
第41卷第7期 王梦玮,徐天蔚,王朝霞,等. PD⁃1/PD⁃L1免疫检查点抑制剂在肺癌临床研究中的进展[J].
2021年7月 南京医科大学学报(自然科学版),2021,41(07):1084-1094 ·1093 ·
[55] MOK T S,WU Y L,THONGPRASERT S,et al. Gefitinib survival with durvalumab after chemoradiotherapy in
or carboplatin ⁃ paclitaxel in pulmonary adenocarcinoma stage Ⅲ NSCLC[J]. N Engl J Med,2018,379(24):
[J]. N Engl J Med,2009,361(10):947-957 2342-2350
[56] KWAK E L,BANG Y J,CAMIDGE D R,et al. Anaplastic [68] GRAY J E,VILLEGAS A,DANIEL D,et al. Three⁃year
lymphoma kinase inhibition in non⁃small⁃cell lung cancer overall survival with durvalumab after chemoradiotherapy
[J]. N Engl J Med,2010,363(18):1693-1703 in stage Ⅲ NSCLC⁃update from PACIFIC[J]. J Thorac
[57] AZUMA K,OTA K,KAWAHARA A,et al. Association of Oncol,2020,15(2):288-293
PD⁃L1 overexpression with activating EGFR mutations in [69] LIN S H,LIN Y,YAO L,et al. Phase Ⅱ trial of concur⁃
surgically resected nonsmall⁃cell lung cancer[J]. Ann On⁃ rent atezolizumab with chemoradiation for unresectable
col,2014,25(10):1935-1940 NSCLC[J]. J Thorac Oncol,2020,15(2):248-257
[58] CHEN N,FANG W,ZHAN J,et al. Upregulation of PD⁃ [70] OTT P A,ELEZ E,HIRET S,et al. Pembrolizumab in pa⁃
L1 by EGFR activation mediates the immune escape in tients with extensive⁃stage small⁃cell lung cancer:results
EGFR ⁃ driven NSCLC:implication for optional immune from the phase Ib KEYNOTE⁃028 study[J]. J Clin Oncol,
targeted therapy for NSCLC patients with EGFR mutation 2017,35(34):3823-3829
[J]. J Thorac Oncol,2015,10(6):910-923 [71] CHUNG H C,PIHA⁃PAUL S A,LOPEZ⁃MARTIN J,et al.
[59] D’INCECCO A,ANDREOZZI M,LUDOVINI V,et al. PD Pembrolizumab after two or more lines of previous therapy
⁃ 1 and PD ⁃ L1 expression in molecularly selected non ⁃ in patients with recurrent or metastatic SCLC:results
small⁃cell lung cancer patients[J]. Br J Cancer,2015,112 from the KEYNOTE⁃028 and KEYNOTE⁃158 studies[J].
(1):95-102 J Thorac Oncol,2020,15(4):618-627
[60] LEE C K,MAN J,LORD S,et al. Clinical and molecular [72] ANTONIA S J,LÓPEZ⁃MARTIN J A,BENDELL J,et al.
characteristics associated with survival among patients Nivolumab alone and nivolumab plus ipilimumab in recur⁃
treated with checkpoint inhibitors for advanced non⁃small rent small⁃cell lung cancer(CheckMate 032):a multicen⁃
cell lung carcinoma:a systematic review and meta⁃analy⁃ tre,open⁃label,phase 1/2 trial[J]. Lancet Oncol,2016,17
sis[J]. JAMA Oncol,2018,4(2):210-216 (7):883-895
[61] GETTINGER S,HELLMANN M D,CHOW L,et al. Niv⁃ [73] READY N,FARAGO A F,DE BRAUD F,et al. Third⁃
olumab plus erlotinib in patients with EGFR⁃mutant ad⁃ line nivolumab monotherapy in recurrent SCLC:Check⁃
vanced NSCLC[J]. J Thorac Oncol,2018,13(9):1363- Mate 032[J]. J Thorac Oncol,2019,14(2):237-244
1372 [74] YANG S,ZHANG Z,WANG Q. Emerging therapies for
[62] AHN M J,SUN J M,LEE S H,et al. EGFR TKI combina⁃ small cell lung cancer[J]. J Hematol Oncol,2019,12
tion with immunotherapy in non ⁃ small cell lung cancer (1):47
[J]. Expert Opin Drug Saf,2017,16(4):465-469 [75] HORN L,MANSFIELD A S,SZCZE SNA A,et al. First⁃
[63] GIBBONS D L,CHOW L Q,KIM D,et al. Efficacy,safety line atezolizumab plus chemotherapy in extensive ⁃ stage
and tolerability of MEDI4736(durvalumab[D]),a human small⁃cell lung cancer[J]. N Engl J Med,2018,379(23):
IgG1 anti⁃programmed cell death⁃ligand⁃1(PD⁃L1)anti⁃ 2220-2229
body,combined with gefitinib(G):a phase I expansion in [76] PAZ⁃ARES L,DVORKIN M,CHEN Y,et al. Durvalumab
TKI⁃naive patients(pts)with EGFR mutant NSCLC[J]. J plus platinum⁃etoposide versus platinum⁃etoposide in first
Thorac Oncol,2016,11S(4):S79 ⁃line treatment of extensive⁃stage small⁃cell lung cancer
[64] AHN M J,YANG J,YU H,et al. Osimertinib combined (CASPIAN):a randomised,controlled,open⁃label,phase
with durvalumab in EGFR ⁃ mutant non ⁃ small cell lung 3 trial[J]. Lancet,2019,394(1212):1929-1939
cancer:results from the TATTON phase Ib trial[J]. J Tho⁃ [77] HELLMANN M D,CALLAHAN M K,AWAD M M,et al.
rac Oncol,2016,11S(4):S115 Tumor mutational burden and efficacy of nivolumab mono⁃
[65] YOON S M,SHAIKH T,HALLMAN M. Therapeutic man⁃ therapy and in combination with ipilimumab in small⁃cell
agement options for stage Ⅲ non⁃small cell lung cancer lung cancer[J]. Cancer Cell,2019,35(2):329
[J]. World J Clin Oncol,2017,8(1):1-20 [78] LE D T,DURHAM J N,SMITH K N,et al. Mismatch re⁃
[66] TOMASINI P,GREILLIER L,BOYER A,et al. Durvalum⁃ pair deficiency predicts response of solid tumors to PD⁃1
ab after chemoradiotherapy in stage Ⅲ non ⁃ small cell blockade[J]. Science,2017,357(6349):409-413
lung cancer[J]. J Thorac Dis,2018,10(Suppl 9):S1032- [79] MCGRANAHAN N,FURNESS A J,ROSENTHAL R,et
S1036 al. Clonal neoantigens elicit T cell immunoreactivity and
[67] ANTONIA S J,VILLEGAS A,DANIEL D,et al. Overall sensitivity to immune checkpoint blockade[J]. Science,